Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Prognostic factors of improvement in health-related quality of life in atomoxetine-treated children and adolescents with attention-deficit/hyperactivity disorder, based on a pooled analysis.

Montoya A, Quail D, Anand E, Cardo E, Alda JA, Escobar R.

Atten Defic Hyperact Disord. 2014 Mar;6(1):25-34. doi: 10.1007/s12402-013-0119-5. Epub 2013 Oct 20.

PMID:
24142305
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Quality of life and attention-deficit/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials.

Escobar R, Schacht A, Wehmeier PM, Wagner T.

J Clin Psychopharmacol. 2010 Apr;30(2):145-51. doi: 10.1097/JCP.0b013e3181d21763.

PMID:
20520287
[PubMed - indexed for MEDLINE]
3.

Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder.

Banaschewski T, Soutullo C, Lecendreux M, Johnson M, Zuddas A, Hodgkins P, Adeyi B, Squires LA, Coghill D.

CNS Drugs. 2013 Oct;27(10):829-40. doi: 10.1007/s40263-013-0095-5.

PMID:
23893527
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Health-related quality of life in ADHD: a pooled analysis of gender differences in five atomoxetine trials.

Wehmeier PM, Schacht A, Escobar R, Hervas A, Dickson R.

Atten Defic Hyperact Disord. 2012 Mar;4(1):25-35. doi: 10.1007/s12402-011-0070-2. Epub 2012 Jan 21.

PMID:
22271466
[PubMed - indexed for MEDLINE]
5.
6.

Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.

Wietecha L, Williams D, Shaywitz S, Shaywitz B, Hooper SR, Wigal SB, Dunn D, McBurnett K.

J Child Adolesc Psychopharmacol. 2013 Nov;23(9):605-13. doi: 10.1089/cap.2013.0054. Epub 2013 Nov 9.

PMID:
24206099
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

Prasad S, Harpin V, Poole L, Zeitlin H, Jamdar S, Puvanendran K; SUNBEAM Study Group.

Curr Med Res Opin. 2007 Feb;23(2):379-94.

PMID:
17288692
[PubMed - indexed for MEDLINE]
8.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
[PubMed - indexed for MEDLINE]
9.

Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder.

Banaschewski T, Johnson M, Lecendreux M, Zuddas A, Adeyi B, Hodgkins P, Squires LA, Coghill DR.

CNS Drugs. 2014 Dec;28(12):1191-203. doi: 10.1007/s40263-014-0193-z.

PMID:
25139785
[PubMed - in process]
Free PMC Article
10.

Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents.

Svanborg P, Thernlund G, Gustafsson PA, Hägglöf B, Schacht A, Kadesjö B.

Eur Child Adolesc Psychiatry. 2009 Dec;18(12):725-35. doi: 10.1007/s00787-009-0031-x. Epub 2009 May 23.

PMID:
19466476
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials.

Schacht A, Escobar R, Wagner T, Wehmeier PM.

Atten Defic Hyperact Disord. 2011 Dec;3(4):335-49. doi: 10.1007/s12402-011-0066-y. Epub 2011 Oct 11.

PMID:
21986814
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.

Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A; LYCY Study Group.

Eur Neuropsychopharmacol. 2009 Nov;19(11):822-34. doi: 10.1016/j.euroneuro.2009.07.008. Epub 2009 Aug 28.

PMID:
19716683
[PubMed - indexed for MEDLINE]
13.

Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.

Durell TM, Adler LA, Williams DW, Deldar A, McGough JJ, Glaser PE, Rubin RL, Pigott TA, Sarkis EH, Fox BK.

J Clin Psychopharmacol. 2013 Feb;33(1):45-54. doi: 10.1097/JCP.0b013e31827d8a23. Erratum in: J Clin Psychopharmacol. 2014 Aug;34(4):542-3.

PMID:
23277268
[PubMed - indexed for MEDLINE]
14.

Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.

Adler LA, Wilens T, Zhang S, Dittmann RW, D'Souza DN, Schuh L, Durell TM.

Clin Ther. 2012 Feb;34(2):363-73. doi: 10.1016/j.clinthera.2011.12.015. Epub 2012 Jan 27.

PMID:
22285724
[PubMed - indexed for MEDLINE]
15.

Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents.

Svanborg P, Thernlund G, Gustafsson PA, Hägglöf B, Poole L, Kadesjö B.

Eur Child Adolesc Psychiatry. 2009 Apr;18(4):240-9. doi: 10.1007/s00787-008-0725-5. Epub 2009 Jan 20.

PMID:
19156355
[PubMed - indexed for MEDLINE]
16.

Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.

Fuentes J, Danckaerts M, Cardo E, Puvanendran K, Berquin P, De Bruyckere K, Montoya A, Quail D, Escobar R.

J Clin Psychopharmacol. 2013 Dec;33(6):766-74. doi: 10.1097/JCP.0b013e31829c762b.

PMID:
23963057
[PubMed - indexed for MEDLINE]
17.

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.

Cheng JY, Chen RY, Ko JS, Ng EM.

Psychopharmacology (Berl). 2007 Oct;194(2):197-209. Epub 2007 Jun 16.

PMID:
17572882
[PubMed - indexed for MEDLINE]
18.

Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.

Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, García-Polavieja MJ, Gilaberte I, Escobar R.

Curr Med Res Opin. 2009 Nov;25(11):2745-54. doi: 10.1185/03007990903316152.

PMID:
19785510
[PubMed - indexed for MEDLINE]
19.

Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.

Klassen AF, Miller A, Fine S.

Pediatrics. 2004 Nov;114(5):e541-7.

PMID:
15520087
[PubMed - indexed for MEDLINE]
20.

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ.

Pediatrics. 2004 Jul;114(1):e1-8.

PMID:
15231966
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk